Naftifine
![]() | |
| Clinical data | |
|---|---|
| Trade names | Exoderil |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a688020 |
| ATC code | D01AE22 (WHO) |
| Identifiers | |
| |
| CAS Number |
65472-88-0 |
| PubChem (CID) | 47641 |
| DrugBank |
DB00735 |
| ChemSpider |
66071 |
| UNII |
4FB1TON47A |
| ChEBI |
CHEBI:7451 |
| ChEMBL |
CHEMBL626 |
| Chemical and physical data | |
| Formula | C21H21N |
| Molar mass | 287.398 g/mol |
| | |
Naftifine (brand name Exoderil) is an allylamine antifungal drug for the topical treatment of tinea pedis, tinea cruris, and tinea corporis (fungal infections).
Naftifine has triple action: antifungal, antibacterial and anti-inflammatory. Its precise mechanism of action is unknown, but may involve selectively blocking sterol biosynthesis via inhibition of the squalene 2,3-epoxidase enzyme.[1][2] The half-life is approximately 2–3 days.[2] The metabolites are excreted in the urine and feces.[3]
References
- ↑ Robertson Dirk B, Maibach Howard I, "Chapter 61. Dermatologic Pharmacology" (Chapter). Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor: Basic & Clinical Pharmacology, 11e: http://www.accesspharmacy.com/content.aspx?aID=4517257.
- 1 2 Micromedex DRUGDEX Drug Point: Naftifine Hydrochloride. Accessed at www.thomsonhc.com/../BeginWith#secN10184, February 18, 2010.
- ↑ AccessPharmacy: Drug Monographs: Naftifine. Accessed at http://www.accesspharmacy.com/drugContentPopup.aspx?mid=6620§ion=10, February 18, 2010.
This article is issued from Wikipedia - version of the 10/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
